SYS-CON MEDIA Authors: Jason Bloomberg, Kevin Benedict, David H Deans, RealWire News Distribution, Gilad Parann-Nissany

News Feed Item

NeoGenomics Announces Next Generation Sequencing Tests for Solid Tumor Cancers and Myelodysplastic Syndrome

Company is First to Offer Plasma-Based Next Generation Sequencing Tests

FORT MYERS, Fla., March 18, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic and molecular testing services, announced today that it has validated and launched the first two of a series of next generation cancer profiling tests.  These tests are designed for profiling myelodysplastic syndrome (MDS) and solid tumor cancers.  Additional cancer-type specific next generation tests are currently being validated and are scheduled for launch over the next several months.

The MDS next generation sequencing (NGS) test can be performed on bone marrow, peripheral blood and plasma samples.  Plasma-based testing for MDS may be used to avoid bone marrow biopsies.  It also has the potential to quantify and monitor tumor load and to detect the emergence of subclones.  The MDS next generation profiling test covers 16 genes involved in the various pathways of MDS, including epigenomics, signal transduction, transcription regulation and spliceosomes.  This test is particularly important for confirming and defining the diagnosis of MDS, which can be extremely difficult in early stages of the disease.

The solid tumor cancer NGS profiling test covers 48 genes and is performed on paraffin-embedded tissue.  This solid tumor profile is extensive and covers the driver genes involved in various types of solid tumor cancers. 

Doug VanOort, the company's Chairman and CEO, said, "NeoGenomics is committed to developing and using cutting edge technology to provide efficient and reliable clinical tests.  We believe that targeted next generation sequencing technology has advanced sufficiently to be offered more routinely in high-throughput clinical laboratory testing for cancer patients.  Importantly, our NGS tests focus on the actionable genes justified medically and financially at this time.  Our NGS profiles are designed for precision testing in order to generate actionable data.  Each of these tests is relevant for diagnosis, predicting prognosis, determining or monitoring therapy, and exploring clinical trials options."

Dr. Maher Albitar, the Company's Chief Medical Officer and Director of Research and Development, commented, "While we do not believe that whole genome or exome NGS is ready for high throughput clinical laboratory testing, targeted NGS provides significant advantages over conventional technology. In fact, the more limited the number of genes analyzed, the more reliable the NGS testing.  Our panel of 16 genes for MDS provides remarkable precision, reliability and sensitivity for the diagnosis, monitoring and management of patients with MDS, especially when performed on peripheral blood plasma. Next generation sequencing is allowing us to further establish plasma-based testing as a practical and more routine testing in hematologic neoplasms."

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that specializes in cancer genetics testing, the fastest growing segment of the laboratory industry.  The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, morphology studies, anatomic pathology and molecular genetic testing.  Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL.  NeoGenomics services the needs of pathologists, oncologists, urologists and other clinicians, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements.  These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements.  Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.

SOURCE NeoGenomics, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.